Marie J Estcourt

List of Publications by Year
in descending order

18	984	840776 11	888059 17
papers	citations	h-index	g-index

18	18	18	1463
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule. Trials, 2022, 23, 121.	1.6	2
2	Wholeâ€cell pertussis vaccine in early infancy for the prevention of allergy in children. The Cochrane Library, 2021, 9, CD013682.	2.8	2
3	Whole-Cell Pertussis Vaccination and Decreased Risk of IgE-Mediated Food Allergy: A Nested Case-Control Study. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2004-2014.	3.8	20
4	Retrospective Case-Control Study of 2017 G2P[4] Rotavirus Epidemic in Rural and Remote Australia. Pathogens, 2020, 9, 790.	2.8	10
5	OPTIMUM study protocol: an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule. BMJ Open, 2020, 10, e042838.	1.9	2
6	Protocol for Pertussis Immunisation and Food Allergy (PIFA): a caseâ€“control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. BMJ Open, 2018, 8, e020232.	1.9	3
7	TRAIL+ NK Cells Control CD4+ T Cell Responses during Chronic Viral Infection to Limit Autoimmunity. Immunity, 2014, 41, 646-656.	14.3	158
8	CpG pretreatment enhances antiviral T-cell immunity against cytomegalovirus. Blood, 2013, 122, 55-60.	1.4	18
9	Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Therapy, 2012, 19, 999-1009.	4.5	46
10	Innate immunity defines the capacity of antiviral T cells to limit persistent infection. Journal of Experimental Medicine, 2010, 207, 1333-1343.	8.5	190
11	rAAV.sFlt-1 Gene Therapy Achieves Lasting Reversal of Retinal Neovascularization in the Absence of a Strong Immune Response to the Viral Vector. , 2009, 50, 4279.		43
12	Altered primary CD8+ Tâ€„cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ Tâ€„cell help. European Journal of Immunology, 2005, 35, 3460-3467.	2.9	8
13	Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ Tâ€„cell responses. European Journal of Immunology, 2005, 35, 2532-2540.	2.9	54
14	Induction of Human Immunodeficiency Virus Type 1-Specific T Cells by a Bluetongue Virus Tubule-Vectored Vaccine Prime-Recombinant Modified Virus Ankara Boost Regimen. Journal of Virology, 2005, 79, 14822-14833.	3.4	22
15	DNA vaccines against human immunodeficiency virus type 1. Immunological Reviews, 2004, 199, 144-155.	6.0	39
16	Primeâ€“boost immunization generates a high frequency, high-avidity CD8+ cytotoxic T lymphocyte population. International Immunology, 2002, 14, 31-37.	4.0	122
17	Cytokine responses in virus infections: effects on pathogenesis, recovery and persistence. Current Opinion in Microbiology, 1998, 1, 411-418.	5.1	30
18	Interferon-resistant Human Melanoma Cells Are Deficient in ISGF3 Components, STAT1, STAT2, and p48-ISGF3Î³. Journal of Biological Chemistry, 1997, 272, 28779-28785.	3.4	215